Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 86384-10-3
2. 5-hydroxy Propafenone
3. Gpv-129
4. 7ac8bf38np
5. Chembl1264
6. 1-[5-hydroxy-2-[2-hydroxy-3-(propylamino)propoxy]phenyl]-3-phenylpropan-1-one
7. 1-propanone, 1-(5-hydroxy-2-(2-hydroxy-3-(propylamino)propoxy)phenyl)-3-phenyl-
8. Unii-7ac8bf38np
9. 1-(5-hydroxy-2-(2-hydroxy-3-(propylamino)propoxy)phenyl)-3-phenylpropan-1-one
10. 1-{5-hydroxy-2-[2-hydroxy-3-(propylamino)propoxy]phenyl}-3-phenylpropan-1-one
11. 1-(5-hydroxy-2-(2-hydroxy-3-(propylamino)propoxy)phenyl)-3-phenyl-1-propanone
12. Schembl2739132
13. Chebi:171897
14. Dtxsid701006775
15. Bdbm50134995
16. Akos000277050
17. Q27266815
18. 1-[5-hydroxy-2-(2-hydroxy-3-propylamino-propoxy)-phenyl]-3-phenyl-propan-1-one
| Molecular Weight | 357.4 g/mol |
|---|---|
| Molecular Formula | C21H27NO4 |
| XLogP3 | 3 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 11 |
| Exact Mass | 357.19400834 g/mol |
| Monoisotopic Mass | 357.19400834 g/mol |
| Topological Polar Surface Area | 78.8 Ų |
| Heavy Atom Count | 26 |
| Formal Charge | 0 |
| Complexity | 398 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 1 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Anti-Arrhythmia Agents
Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)
Adrenergic beta-Antagonists
Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety. (See all compounds classified as Adrenergic beta-Antagonists.)
5-Hydroxypropafenone is a known human metabolite of Propafenone.
S73 | METXBIODB | Metabolite Reaction Database from BioTransformer | DOI:10.5281/zenodo.4056560
ANALYTICAL
ABOUT THIS PAGE
A 5-Hydroxypropafenone manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of 5-Hydroxypropafenone, including repackagers and relabelers. The FDA regulates 5-Hydroxypropafenone manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. 5-Hydroxypropafenone API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A 5-Hydroxypropafenone supplier is an individual or a company that provides 5-Hydroxypropafenone active pharmaceutical ingredient (API) or 5-Hydroxypropafenone finished formulations upon request. The 5-Hydroxypropafenone suppliers may include 5-Hydroxypropafenone API manufacturers, exporters, distributors and traders.
5-Hydroxypropafenone Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of 5-Hydroxypropafenone GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right 5-Hydroxypropafenone GMP manufacturer or 5-Hydroxypropafenone GMP API supplier for your needs.
A 5-Hydroxypropafenone CoA (Certificate of Analysis) is a formal document that attests to 5-Hydroxypropafenone's compliance with 5-Hydroxypropafenone specifications and serves as a tool for batch-level quality control.
5-Hydroxypropafenone CoA mostly includes findings from lab analyses of a specific batch. For each 5-Hydroxypropafenone CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
5-Hydroxypropafenone may be tested according to a variety of international standards, such as European Pharmacopoeia (5-Hydroxypropafenone EP), 5-Hydroxypropafenone JP (Japanese Pharmacopeia) and the US Pharmacopoeia (5-Hydroxypropafenone USP).
LOOKING FOR A SUPPLIER?
